The broad spectrum of myelodysplastic syndromePosted: June 3, 2016
Ellen Ritchie, M.D., assistant professor of clinical medicine, joins OncLive in a discussion on the current best practices in the management of myelodysplastic syndrome and how the latest research is likely to impact the field.
“I think it’s very important when we talk to patients about MDS that we talk about the broad spectrum of disease and that we don’t label it as cancer necessarily. Because I think that it can almost be as detrimental to their quality of life with the disease afterward, by labeling it as such, than the treatments and supportive care that we have to give them.” – Dr. Ellen Ritchie
To learn more about our CRUSH!!MDS program and to participate in a clinical trial [go]